Literature DB >> 21125431

Pulmonary complications of cirrhosis.

Rajan Kochar1, Moises I Nevah Rubin, Michael B Fallon.   

Abstract

Pulmonary vascular complications of liver disease comprise two distinct clinical entities: hepatopulmonary syndrome (HPS-microvascular dilatation and angiogenesis) and portopulmonary hypertension (POPH-vasoconstriction and remodeling in resistance vessels). These complications occur in similar pathophysiologic environments and may share pathogenic mechanisms. HPS is found in 15% to 30% of patients with cirrhosis and its presence increases mortality and the risks of liver transplantation, particularly when hypoxemia is present. Contrast echocardiography and arterial blood gas analysis are required to establish the diagnosis. No medical therapies are available, although liver transplantation is effective in reversing the syndrome. POPH is found in 4% to 8% of patients undergoing liver transplantation evaluation, and the presence of moderate to severe disease significantly increases perioperative transplant mortality. Transthoracic echocardiography is recommended for screening and right-heart catheterization is required to establish the diagnosis. Medical therapies are increasingly effective in improving pulmonary vascular hemodynamics in POPH and may result in better perioperative outcomes.

Entities:  

Mesh:

Year:  2011        PMID: 21125431     DOI: 10.1007/s11894-010-0164-6

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  48 in total

1.  Portopulmonary hypertension: diagnostic advances and caveats.

Authors:  Michael J Krowka
Journal:  Liver Transpl       Date:  2003-12       Impact factor: 5.799

2.  Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation.

Authors:  Miguel R Arguedas; Gary A Abrams; Michael J Krowka; Michael B Fallon
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

Review 3.  Pulmonary-Hepatic vascular Disorders (PHD).

Authors:  R Rodríguez-Roisin; M J Krowka; Ph Hervé; M B Fallon
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

4.  Hepatopulmonary syndrome in candidates for liver transplantation.

Authors:  G P Martínez; J A Barberà; J Visa; A Rimola; J C Paré; J Roca; M Navasa; J Rodés; R Rodriguez-Roisin
Journal:  J Hepatol       Date:  2001-05       Impact factor: 25.083

Review 5.  The hepatopulmonary syndrome.

Authors:  P A Lange; J K Stoller
Journal:  Ann Intern Med       Date:  1995-04-01       Impact factor: 25.391

6.  Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates.

Authors:  M Torregrosa; J Genesca; A Gonzalez; A Evangelista; A Mora; C Margarit; R Esteban; J Guardia
Journal:  Transplantation       Date:  2001-02-27       Impact factor: 4.939

7.  Methylene blue improves the hepatopulmonary syndrome.

Authors:  P Schenk; C Madl; S Rezaie-Majd; S Lehr; C Müller
Journal:  Ann Intern Med       Date:  2000-11-07       Impact factor: 25.391

8.  Utility of pulse oximetry in the detection of arterial hypoxemia in liver transplant candidates.

Authors:  Gary A Abrams; Michael K Sanders; Michael B Fallon
Journal:  Liver Transpl       Date:  2002-04       Impact factor: 5.799

Review 9.  Screen for portopulmonary hypertension, especially in liver transplant candidates.

Authors:  Karen L Swanson; Michael J Krowka
Journal:  Cleve Clin J Med       Date:  2008-02       Impact factor: 2.321

10.  Experience with inhaled iloprost and bosentan in portopulmonary hypertension.

Authors:  M M Hoeper; H J Seyfarth; G Hoeffken; H Wirtz; E Spiekerkoetter; M W Pletz; T Welte; M Halank
Journal:  Eur Respir J       Date:  2007-07-25       Impact factor: 16.671

View more
  1 in total

1.  A novel molecular signature for elevated tricuspid regurgitation velocity in sickle cell disease.

Authors:  Ankit A Desai; Tong Zhou; Homaa Ahmad; Wei Zhang; Wenbo Mu; Sharon Trevino; Michael S Wade; Nalini Raghavachari; Gregory J Kato; Marlene H Peters-Lawrence; Tejas Thiruvoipati; Kristin Turner; Nicole Artz; Yong Huang; Amit R Patel; Jason X-J Yuan; Victor R Gordeuk; Roberto M Lang; Joe G N Garcia; Roberto F Machado
Journal:  Am J Respir Crit Care Med       Date:  2012-06-07       Impact factor: 21.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.